Cargando…
The delivery of therapeutic oligonucleotides
The oligonucleotide therapeutics field has seen remarkable progress over the last few years with the approval of the first antisense drug and with promising developments in late stage clinical trials using siRNA or splice switching oligonucleotides. However, effective delivery of oligonucleotides to...
Autor principal: | Juliano, Rudolph L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5001581/ https://www.ncbi.nlm.nih.gov/pubmed/27084936 http://dx.doi.org/10.1093/nar/gkw236 |
Ejemplares similares
-
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
por: Juliano, Rudy, et al.
Publicado: (2008) -
Splice-switching antisense oligonucleotides as therapeutic drugs
por: Havens, Mallory A., et al.
Publicado: (2016) -
Phosphorothioate modified oligonucleotide–protein interactions
por: Crooke, Stanley T, et al.
Publicado: (2020) -
Target mRNA inhibition by oligonucleotide drugs in man
por: Lightfoot, Helen L., et al.
Publicado: (2012) -
Oligonucleotide-based strategies to combat polyglutamine diseases
por: Fiszer, Agnieszka, et al.
Publicado: (2014)